Insulet Corporation with ticker code (PODD) have now 18 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $270.00 and $163.00 suggesting an average Analsyt target price of $217.67. Given that the stocks previous close was at $192.19 and the analysts are correct then there would likely be a percentage uptick in value of 13.3%. The 50 day moving average now sits at $157.57 and the 200 moving average now moves to $245.13. The market capitalization for the company is 13.55B. The stock price for the company is currently is currently $193.99 USD
The potential market cap would be $15,341,726,810 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 112.13, revenue per share of $22.35 and a 2.36% return on assets.
Insulet Corporation is primarily engaged in the development, manufacture and sale of its Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System features a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin, and the Personal Diabetes Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta.
